MARC-ANTOINE B.
- Country
- France
- Department
- Oncologie Médicale
Research Overview
- De‑escalation of Neoadjuvant Carboplatin‑Paclitaxel Plus Pembrolizumab in Stage II Triple‑Negative Breast Cancer with High Tumor‑Infiltrating Lymphocytes
- Randomized Evaluation of Paclitaxel-Carboplatin with Maintenance Niraparib versus Paclitaxel-Carboplatin-Bevacizumab with Maintenance Niraparib-Bevacizumab in Advanced Ovarian Cancer
- Phase 3 Randomized, Double-Blind Study of Platinum-Based Therapy with Dostarlimab and Niraparib vs. Standard Care in Stage III/IV Non-Mucinous Epithelial Ovarian Cancer
Data & Insights
Has run more than one trial at 65 of 192 partner sites.
Specializations
Breast Cancer Research
Specialized in investigating advanced therapeutic approaches for various breast cancer subtypes, with particular focus on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments.
- Advanced breast cancer therapies
- Triple-negative breast cancer treatments
- Early-stage breast cancer interventions
Expertise in evaluating novel therapeutic combinations including targeted therapies and immunotherapy approaches.
Gynecologic Oncology
Conducts research in advanced treatments for ovarian cancer, focusing on innovative therapeutic combinations and maintenance strategies.
- Advanced ovarian cancer treatment
- Peritoneal cancer therapy
- Fallopian tube cancer management
Specializes in evaluating combination approaches using targeted therapies and immunotherapeutic agents.
Therapeutic Innovation
Explores cutting-edge treatment modalities including antibody-drug conjugates and novel therapeutic combinations for complex oncological conditions.
- Targeted therapy development
- Immunotherapy applications
- Combination treatment strategies
Focuses on developing personalized treatment approaches based on specific biomarkers and genetic profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.